Pegylated Interferon Lambda for Covid-19

Affiliations

¹ Zhengzhou University People's Hospital, Zhengzhou, China.
² Shulan Hospital, Hangzhou, China.
³ First Affiliated Hospital of Zhejiang University, Hangzhou, China lingtonghuang@zju.edu.cn.

Comment

Mingqiang Wang et al. N Engl J Med. 2023.

. 2023 Jun 1;388(22):2107-2108.

doi: 10.1056/NEJMc2303519.

¹ Zhengzhou University People's Hospital, Zhengzhou, China.
² Shulan Hospital, Hangzhou, China.
³ First Affiliated Hospital of Zhejiang University, Hangzhou, China lingtonghuang@zju.edu.cn.

No abstract available

Comment on

Early Treatment with Pegylated Interferon Lambda for Covid-19.
Reis G, Moreira Silva EAS, Medeiros Silva DC, Thabane L, Campos VHS, Ferreira TS, Santos CVQ, Nogueira AMR, Almeida APFG, Savassi LCM, Figueiredo-Neto AD, Dias ACF, Freire Júnior AM, Bitarães C, Milagres AC, Callegari ED, Simplicio MIC, Ribeiro LB, Oliveira R, Harari O, Wilson LA, Forrest JI, Ruton H, Sprague S, McKay P, Guo CM, Limbrick-Oldfield EH, Kanters S, Guyatt GH, Rayner CR, Kandel C, Biondi MJ, Kozak R, Hansen B, Zahoor MA, Arora P, Hislop C, Choong I, Feld JJ, Mills EJ, Glenn JS; TOGETHER Investigators. Reis G, et al. N Engl J Med. 2023 Feb 9;388(6):518-528. doi: 10.1056/NEJMoa2209760. N Engl J Med. 2023. PMID: 36780676 Free PMC article. Clinical Trial.